Paper39604266
A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.
Holt BD and 9 others. Mol Ther, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease. Papers, record 39604266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39604266
- Instrument
- Rotarod Test18 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A novel CD71 Centyrin:Gys1 siRNA conjugate reduces glycogen synthesis and glycogen levels in a mouse model of Pompe disease.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Instruments1
Source Instruments
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glycogen Storage Disease Type II | Major topic |
| Glycogen | Major topic |
| Disease Models, Animal | Major topic |
| RNA, Small Interfering | Major topic |
| Animals | |
| Mice | |
| Humans | |
| Receptors, Transferrin | |
| Antigens, CD | |
| Muscle, Skeletal | |
| Glycogen Synthase |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18232732 | A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice. | PLoS Med | 2008 | https://conductscience.org/library/papers/18232732 | PubMed |
| 2 | 9668092 | Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9668092 | PubMed |
| 3 | 22992140 | Immune modulation in Pompe disease treated with enzyme replacement therapy. | Expert Rev Clin Immunol | 2012 | https://conductscience.org/library/papers/22992140 | PubMed |
| 4 | 40268518 | Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40268518 | PubMed |
| 5 | 11283248 | Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. | Mol Cell Biol | 2001 | https://conductscience.org/library/papers/11283248 | PubMed |
| 6 | 34506219 | Regulation and role of glycophagy in skeletal muscle energy metabolism. | Autophagy | 2022 | https://conductscience.org/library/papers/34506219 | PubMed |
| 7 | 20865334 | Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. | J Inherit Metab Dis | 2010 | https://conductscience.org/library/papers/20865334 | PubMed |
| 8 | 17151339 | Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. | Neurology | 2007 | https://conductscience.org/library/papers/17151339 | PubMed |
| 9 | 36257298 | Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. | Med | 2022 | https://conductscience.org/library/papers/36257298 | PubMed |
| 10 | 12897283 | The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. | Pediatrics | 2003 | https://conductscience.org/library/papers/12897283 | PubMed |
| 11 | 15711014 | Exercise capacity of mice genetically lacking muscle glycogen synthase: in mice, muscle glycogen is not essential for exercise. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15711014 | PubMed |
| 12 | 33601052 | Centyrin ligands for extrahepatic delivery of siRNA. | Mol Ther | 2021 | https://conductscience.org/library/papers/33601052 | PubMed |
| 13 | 37823690 | Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. | MAbs | 2023 | https://conductscience.org/library/papers/37823690 | PubMed |
| 14 | 21259334 | Brain glycogen supercompensation in the mouse after recovery from insulin-induced hypoglycemia. | J Neurosci Res | 2011 | https://conductscience.org/library/papers/21259334 | PubMed |
| 15 | 26977394 | Impaired glucose metabolism and exercise capacity with muscle-specific glycogen synthase 1 (gys1) deletion in adult mice. | Mol Metab | 2016 | https://conductscience.org/library/papers/26977394 | PubMed |
| 16 | 28895054 | A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice. | Mol Neurobiol | 2018 | https://conductscience.org/library/papers/28895054 | PubMed |
| 17 | 17510371 | Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model. | J Histochem Cytochem | 2007 | https://conductscience.org/library/papers/17510371 | PubMed |
| 18 | 36111639 | Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism. | J Inherit Metab Dis | 2023 | https://conductscience.org/library/papers/36111639 | PubMed |
| 19 | 23457523 | Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease. | PLoS One | 2013 | https://conductscience.org/library/papers/23457523 | PubMed |
| 20 | 16306363 | Glucose metabolism in mice lacking muscle glycogen synthase. | Diabetes | 2005 | https://conductscience.org/library/papers/16306363 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42923624 | Infantile-Onset Pompe Disease: Current Therapeutic Landscape, Clinical Challenges, and Future Horizons. | Cureus | 2026 | https://conductscience.org/library/papers/42923624 | PubMed |
| 41948007 | Unifying the Communities of Early-Onset Glycogen Storage Disease Type IV and Adult Polyglucosan Body Disease Through a Genetic Prevalence Study of GBE1-Related Disease. | JIMD Rep | 2026 | https://conductscience.org/library/papers/41948007 | PubMed |
| 41783848 | Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions. | Front Neurol | 2026 | https://conductscience.org/library/papers/41783848 | PubMed |
| 41621836 | RNA-Based Therapies for Inherited Metabolic Disorders. | J Inherit Metab Dis | 2026 | https://conductscience.org/library/papers/41621836 | PubMed |
| 41442049 | New advances in treating late-onset Pompe Disease: A narrative review. | Eur J Pediatr | 2025 | https://conductscience.org/library/papers/41442049 | PubMed |
| 41432033 | Potent and durable gene modulation in heart and muscle with chemically defined lipophilic siRNAs. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/41432033 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GAA | 2548 | PubTator's text mining | https://conductscience.org/library/genes/2548 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39604266
GET https://conductscience.org/api/papers/v1/39604266/references?page=2